title: Local delivery of heparin with balloon angioplasty: results of a prospective randomized trial.
abstract: OBJECTIVE
  To evaluate the effectiveness of local delivery of heparin via hydrogel-coated balloons in the treatment of vascular stenoses associated with hemodialysis access.
  
  
  METHODS
  This was a randomized, prospective trial comparing treatment with hydrogel-coated balloon catheters delivered with heparin coating (n = 33) and without (n = 26). All patients were undergoing hemodialysis, and all stenoses involved the venous anastomosis of a dialysis graft or a native vein. The heparin-treated balloons were soaked in concentrated heparin and delivered in a protected manner to help prevent washout of heparin.
  
  
  RESULTS
  The mean primary patencies were 143 days with heparin treatment and 214 days without heparin (P = .174). The mean assisted primary patencies were 165 days with heparin and 194 days without (P = .315). The mean secondary patencies were 351 days with heparin and 384 without (P = .81).
  
  
  CONCLUSIONS
  In this population with this technique, the treatment outcome of venous outflow stenosis in patients with dialysis grafts is not improved with local delivery of heparin.
authors.affiliation: Department of Radiology, Legacy Good Samaritan Hospital and Medical Center, Portland, OR 97210, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Sheley
authors.forename: E S
authors.initials: ES
authors.lastname: Schuman
authors.forename: B A
authors.initials: BA
authors.lastname: Standage
authors.forename: J W
authors.initials: JW
authors.lastname: Ragsdale
authors.forename: P D
authors.initials: PD
authors.lastname: Feliciano
authors.forename: S F
authors.initials: SF
authors.lastname: Quinn
mesh_terms: D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D001166:Arteriovenous Shunt, Surgical; D005260:Female; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011446:Prospective Studies; D006435:Renal Dialysis; D013997:Time Factors; D014654:Vascular Patency
chemical_list: D000925:Anticoagulants; D011138:Polytetrafluoroethylene; D006493:Heparin